Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Randomized Double-blind Placebo-controlled Prospective Study to Evaluate the Safety and Efficacy of the Direct Factor Xa Inhibitor Dimolegin (DD217) in Prevention of Venous Thromboembolic Complications During Knee Replacement

NCT05189002 is registered in ClinicalTrials.gov with PharmaDiall Ltd. as lead sponsor.

NCT NCT05189002
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05189002 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Randomized Double-blind Placebo-controlled Prospective Study to Evaluate the Safety and Efficacy of the Direct Factor Xa Inhibitor Dimolegin (DD217) in Prevention of Venous Thromboembolic Complications During Knee Replacement
Lead sponsor
PharmaDiall Ltd.
Phase
Phase 2
Overall status
Unknown status
Start date
May 31, 2019
Completion date
December 31, 2022
Enrollment
240 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

venous thromboembolism